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The aim of this study is to determine effects of size deviations of brachytherapy seeds
on  two dimensional dose distributions around the seed. Although many  uncertainties are
well  known, the uncertainties which stem from geometric features of radiation sources are
weakly considered and predicted. Neither TG-43 report which is not completely in common
consensus, nor individual scientiﬁc MC and experimental studies include sufﬁcient data
for  geometric uncertainties. Sizes of seed and its components can vary in a manufacturing
deviation. This causes geometrical uncertainties, too. In this study, three seeds which have
different geometrical properties were modeled using EGSnrc-Code Packages. Seeds were
designed with all their details using the geometry package. 5% deviations of seed sizes were
assumed. Modiﬁed seeds were derived from original seed by changing sizes by 5%. Normal-onte Carlo
GSnrc
izations of doses which were calculated from three kinds of brachytherapy seed and their
derivations were found to be about 3%–20%. It was shown that manufacturing differences
of  brachytherapy seed cause considerable changes in dose distribution.
©  2014 Published by Elsevier Urban & Partner Sp. z o.o. on behalf of Greater Poland Cancer.  Introduction
onte Carlo (MC) simulations are popular and relatively reli-
ble for brachytherapy. TG-43 (Task Group) report of the
APM (the American Association of Physicists in Medicine) col-
ects both experimental and MC  data and evaluates them.
he uncertainty of data of applied dose is momentous for
edical-dosimetric studies because of human life. It is aimedhat optimum dose value must be acquired in cancerous tis-
ue to treat it in radiotherapy (brachytherapy is specialized
adiotherapy). There are several uncertainties of dose and they
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must be determined completely to decide an optimum value
in treatment planning.
Low dose rate (LDR) brachytherapy sources are commonly
used for cancer treatment especially for prostate cancer. The
dose distribution around a brachytherapy seed source is cal-
culated in a formalism that is suggested in AAPM Task Group
43 Report for the treatment planning. As the TG-43 formalism
the dose is calculated as follows: Camgöz), mehmet.nurullah.kumru@ege.edu.tr (M.N. Kumru).
D˙(r, ) = Sk
G(r, )
G(r0, 0)
g(r)F(r, ) (1)
.o. on behalf of Greater Poland Cancer Centre.
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at a point speciﬁed by r and  variables where  is dose rate
constant and Sk is air kerma strength. Radial dose function
g(r) and anisotropy function F(r,) are calculated using ana-
lytical dose values. This formalism requires the usage of a
number of dosimetry parameters for the calculation of dose
value at a certain point around a brachytherapy source. It
is also assumed that a brachytherapy source has an ideal
geometry (announced manufacturer speciﬁcations). Eq. (1)
was performed by partitioned functions. Uncertainties of each
expression which perform main dose value have a contribu-
tion on total uncertainties. Although individual uncertainties
are assumed small as they can be omitted they are effective
on total uncertainties. As it is understood from the equa-
tion, dosimetric functions and main dose D(r,) quantity is
directly dependent on geometrical variables. Components of
a brachytherapy seed have speciﬁc sizes.1 Seed models vary
from one another with their general shape, material thick-
ness, length, radius, radioactivity carrier properties, kind of
radio-opaque material and radioactive material. All of these
properties directly affect and change analytical dose value
around the source.1 Accurate knowledge of source geometry
and details of its physical structure are especially impor-
tant for Monte Carlo modeling.1 Monte Carlo simulations
are independent from detector-source geometry and detec-
tor response artifacts. Smaller estimated uncertainty can
cause artifact-free dose-rate estimates at distances shorter or
longer than those accessible by TLD (Thermo Luminescence
Dosimeter) methods. Few Monte Carlo studies have been
conducted to determine the effects of geometric uncertain-
ties, internal component mobility, size variations of sources,
and on the uncertainty of dose distributions.1 Geometrical
changes will contribute with an external uncertainty over
other known uncertainties on dosimetric parameters in Eq.
(1) which results in the analytical dose value. Estimation
of geometric uncertainty, %|G, is complex and not well
understood.1 Each source design is characterized by numer-
ous and unique geometric parameters, most of which have
unknown and potentially correlated probability distributions.
However, a few studies in the literature report parametric
studies in which the sensitivity of dosimetric parameters to
speciﬁed sources of geometric variability is published.1 For
example, Williamson4 has shown that the distance between
the two radioactive spherical pellets of the Drax Image  (Jubi-
lant DraxImage Incorporated. 16751 Trans-Canada Highway
Kirkland, Québec, Canada H9H 4J4) 125I source varies from 3.50
to 3.77 mm.  This leads to a source-orientation dependent vari-
ation of approximately 5% in calculated dose-rate constant.
Rivard2 published similar ﬁndings for the NASI (North Amer-
ican Scientiﬁc) model MED3631-A/M (Brachytherapy Services
Incorporated (BSI) 7643 Fullerton Road, Springﬁeld, VI 22153,
USA) 125I source.
For the DraxImage (Jubilant DraxImage Inc.) seed model3
source %|geo = 1.4%. For the Theragenics Corporation Model
200 seed, Williamson has shown that L is relatively insensi-
tive to Pd metal layer thickness or end weld conﬁguration.4
Thus 2% seems to be a reasonable and conservative estimate
of %|geo. The reported statistical precision of Monte Carlo
 estimates ranges from 0.5% for Williamson’s recent studies
to 3% for Rivard’s MED3631-A/M (Brachytherapy Services Inc.)
study.5 Thus for a typical Williamson study, one obtains a %iotherapy 1 9 ( 2 0 1 4 ) 301–309
of 2.5%. Using the %|s reported by each investigator along
with the standard %|geo and %| values, discussed above;
% varies from 2.5% to 3.7% for the eight seeds described in
this report. Thus, assuming a standard or generic % of 3%
for all Monte Carlo studies seems reasonable.1
Mobit and Badragan6 noted geometrical speciﬁcations of
Amersham (Nycomed Amersham) Model 6711 (Oncura Incor-
porated, 3350 North Ridge Avenue, Arlington Heights, IL 60004,
USA) Seed. Their measurements (Table 1) showed that all man-
ufactured seeds are not equal to each other and producing
speciﬁcs. In that data (Table 1) dimensional uncertainties in
Table 1 between 1% and 4%”. Table 1 provides reference data
to limit deviation amounts of components of the seeds.
Goal of this study is to examine geometrical deviations of
brachytherapy seeds on dosimetric distribution. In this study,
three seeds which have different geometrical properties were
modeled using EGSnrc-Code Packages. Seeds were designed
in all their detail with the geometry package. 5% deviations of
seed sizes were assumed. Modiﬁed seeds were derived from
the original seed by changing sizes by 5%.
There are several kind of geometrical uncertainty sources
for brachytherapy seeds.7 MC investigators should be free from
manufacturing speciﬁcs of a seed.7 In this study hypotheti-
cal seeds which have been derived are used to characterize
some of source geometry uncertainty. Probable deviation of
seed dimensions8 was selected as some of geometrical uncer-
tainties.
2.  Materials  and  methods
In the present study Amersham Model 6711 (Oncura Inc.),
TheraSeed 200 (Theragenics Corporation, 5203 Bristol Indus-
trial Way, Buford, GA 30518, USA) and Imagyin Seed (Imagyn
Medical Technologies, Incorporated, 1 Park Plaza Ste 1100,
Irvine, CA 92614, USA) were modeled using EGSnrc9 Monte
Carlo Code.
Scenarios of geometric variations of seeds reference seed
that has ideal geometrical measurements published by com-
mercials were simulated using this code. Every geometrical
combination of seed component performed hypothetic seeds
which had been derived from the commercial one. Dose was
calculated by mathematical process of EGS Simulation as
Dj = Kj
col
=
∑
i
Eiti(en/)
Vj
where Dj and Kj
col
are the dose and collision kerma in the jth
voxel, Ei is the energy of the ith photon, and ti is the track
length of that photon in the voxel. The mass-energy absorp-
tion coefﬁcient corresponding to energy Ei is (en/)  and Vj is
the volume of the voxel.10 Voxels were dimensioned (Fig. 1)
with optimum volume values according to Taylor et al.10
2.1.  Seed  modeling
Designed seeds and their geometrical derivative seed models
were identiﬁed by identiﬁcation (ID) number. Derivative seed
concepts were designed by changing seed dimensions11
with 5% ratios (Tables 2–4). This size diversity supplies large
probability for practical seed properties. It must be mentioned
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Table 1 – For Model 6711 seed geometrical measurements show deviations among manufactured seeds. Mobit and
Badragan6 have taken the data from Sloboda and Menon’s study.8
Seed number Ti capsule Silver rod
Length (mm)  Diameter (mm)  Length (mm)  Diameter (mm)
1 4.75 ± 0.01 0.80 ± 0.01 2.88 ± 0.04 0.57 ± 0.04
2 4.57 ± 0.01 0.80 ± 0.01 2.82 ± 0.04 0.56 ± 0.04
3 4.62 ± 0.01 0.79 ± 0.01 2.84 ± 0.04 0.55 ± 0.04
4 4.54 ± 0.01 0.80 ± 0.01 2.84 ± 0.04 0.55 ± 0.04
5 4.66 ± 0.01 0.80 ± 0.01 2.90 ± 0.04 0.55 ± 0.04
6 4.58 ± 0.01 0.80 ± 0.01 2.84 ± 0.04 0.55 ± 0.04
7 4.52 ± 0.01 0.80 ± 0.01 2.90 ± 0.04 0.55 ± 0.04
8 4.59 ± 0.01 0.80 ± 0.01
Average 4.60 ± 0.01 0.80 ± 0.01
Fig. 1 – Voxels were  generated by cutting rectilinear
phantom into intersected slabs. Voxel is a term that was
derived from pixel for three dimensions. Voxel is a volume
element.
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Table 4. The seed consists of the main titanium cylinder cap-hat, although three seeds are previously studied by several
cientists, these seeds were used to represent different kinds
f seed geometries in recent study instead of studying their
osimetric characteristics. Novel approximation of this study
s related to seed component designed separately. Separately
esigned elements were given sub-ID numbers which are
ound to the main seed ID number. This technique enabled
o easily change sizes of components separately to produce
robable seed situations. ID systematics of modeling was
nspired by the logic of 3D drawing software such as 3DsMax.
Fig. 2 – Cross sections of Model 6711 seed: (a) longitudinal c
Fig. 3 – Cross sections of TheraSeed 200: (a) longitudinal cr2.90 ± 0.04 0.55 ± 0.04
 2.87 ± 0.04 0.55 ± 0.04
ID numbers were not chosen systematically. They were a
completely personal decision.
2.2.  Amersham  Model  6711  I-125  (Oncura  Inc.)
Original seed was identiﬁed by 2090 ID number as shown in
Table 2. The seed consists of the main titanium cylinder cap-
sule that is sealed by titanium semi spheres on its both sides.
It contains 125I adsorbed argent core. This seed has general
and simple brachytherapy seed geometry (Fig. 2).
2.3.  Theragenics  200  Pd-103  (Theragenics
Corporation)
Original seed was identiﬁed by 2200 ID number as seen in
Table 3. The seed consists of the main titanium cylinder cap-
sule that is sealed by titanium semi spherical concave shells.
There are two graphite pellets that contain 103Pd placed at both
sides of the lead marker (Fig. 3)
2.4.  Imagyn  Seed  I-125  (Imagyn  Medical  Technologies
Inc.)
Original seed was identiﬁed by 2110 ID number as seen insule that is sealed by titanium semi spheres likely Model 6711.
Inside the capsule there are ﬁve argent spheres (Fig. 4) which
contain 125I.
ross section and (b) transverse cross section (ID: 2090).
oss section and (b) transverse cross section (ID: 2200).
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Fig. 4 – Cross sections of ImagynSeed: (a) longitudinal cross section and (b) transverse cross section (ID: 2090).
Table 2 – Geometrical variation data of derived seeds from Model 6711 source were  obtained by changing 5% ratios of
original dimensions. Each designed model was identiﬁed by an ID number. ID numbers will be standard in database of
MG Package Code. Original seed ID is 2090.
ID Capsule length, Lc (cm) Capsule thickness, Tc (cm) Core length, L (cm) Core radius, Rc (cm)
2090 0.45 0.005 0.3 0.025
2060 0.45 0.007 0.3 0.025
2064 0.45 0.005 0.3 0.02625
2065 0.45 0.007 0.3 0.02625
2066 0.4725 0.005 0.3 0.025
2069 0.45 0.005 0.315 0.025
2071 0.4275 0.005 0.3 0.025
2074 0.45 0.005 0.285 0.025
2076 0.4275 0.005 0.285 0.025
2077 0.4725 0.005 0.315 0.025
Table 3 – Geometrical variation data of derived seeds from TheraSeed 200 source were  obtained by changing 5% ratios of
original dimensions. Each designed model was identiﬁed by an ID number. ID numbers will be standard in database of
MG Package Code. Original seed ID is 2200.
ID Capsule
length, Lc (cm)
Capsule
thickness, Tc (cm)
Marker length,
Lm (cm)
Marker radius,
Rm (cm)
Core length,
L  (cm)
Core radius,
Rc (cm)
2200 0.45 0.005 0.0545 0.0225 0.0445 0.028
2250 0.45 0.0072 0.0545 0.0225 0.0445 0.028
2253 0.45 0.005 0.0545 0.0225 0.0445 0.0294
2257 0.45 0.0072 0.0545 0.0225 0.0445 0.0294
2258 0.4725 0.005 0.0545 0.0225 0.0445 0.028
2261 0.45 0.005 0.0545 0.0225 0.04672 0.028
2265 0.4275 0.005 0.0545 0.0225 0.0445 0.028
2268 0.45 0.005 0.0545 0.0225 0.04227 0.028
2272 0.4275 0.005 0.0545 0.0225 0.04227 0.028
2273 0.4725 0.005 0.0545 0.0225 0.04672 0.028
545 
545 
545 2274 0.45 0.00293 0.0
2277 0.45 0.005 0.0
2281 0.45 0.00293 0.0
After identiﬁcation of seed size situations by several modi-
ﬁed or derived seed models, seed combinations were acquired
as seen in Tables 2–4. Combinations of seed size deviations
were performed using Table 1 data reference. Situation types
and ID numbers were expressed as.
Table 4 – Geometrical variation data of derived seeds from Imag
original dimensions. Each designed model was identiﬁed by an
MG Package Code. Original seed ID is 2110.
ID Capsule length, Lc (cm) Cap
2110 0.37 
2310 0.37 
2311 0.37 
2312 0.37 
2320 0.37 
2328 0.37 
2329 0.37 
2330 0.3885 
2331 0.3515 
2332 0.3515 
2333 0.3885 0.0225 0.0445 0.028
0.0225 0.0445 0.0266
0.0225 0.0445 0.0266
2.5.  Dose  calculation  methodDosimetric parameters are analytical functions dependent on
radial and angular variables on a deﬁned P(r,) point however
the dose cannot be described in a dimensionless point. A small
yn Seed source were  obtained by changing 5% ratios of
 ID number. ID numbers will be standard in database of
sule thickness, Tc (cm) Core radius, Rc (cm)
0.05 0.032
0.07 0.032
0.03 0.032
0.05 0.0336
0.05 0.0304
0.07 0.0336
0.03 0.0304
0.05 0.032
0.05 0.032
0.05 0.0304
0.05 0.0366
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Fig. 5 – Analytic system of Monte Carlo calculation for phantom design. Dose values of modiﬁed seeds were  acquired in the
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olume that includes P point was assumed to calculate analyt-
cal dose data. These volumes which are named as voxels were
onstructed in an optimum size.10 Dose distribution in water
as calculated based on a cubic water phantom. 1D dose val-
es were extracted from 3D dose data in the phantom (Fig. 5).
adial distributions of modiﬁed and original seed models were
alculated on single axis of Cartesian system using two differ-
nt phantoms with dimensions of 0.1 mm × 0.1 mm × 0.1 mm
oxels and dimensions of 0.5 mm × 0.5 mm × 0.5 mm voxel to
ormalize dose distribution data of modiﬁed seeds in the
0 cm,  1 cm]  and [0 cm,  5 cm]  scale..  Results  and  discussion
GSnrc Monte Carlo simulation and the AAPM-TG43 dosime-
ry protocol is generally within 10% for radial distances smaller
Fig. 6 – Dose normalizations for Mod using the xyz rectilinear phantom (it is referred to in
than 2.5 cm but increases to 20% for radial distances greater
than 3.0 cm.  As the polar angle decreases and the radius
increases, the difference between Monte Carlo simulation and
the AAPM-TG43 dosimetry protocol increases. In the longitu-
dinal direction of the source, there are differences greater than
20% between EGSnrc Monte Carlo simulations and the AAPM-
TG43 dosimetry protocol for radial distances between 0.5 cm
and 2.0 cm.  The differences increase to more  than 40% for
radial distances greater than 2.5 cm in the longitudinal direc-
tion of the6 source. Obviously, these considerations do not
include geometrical effects. Dose deviations were processed
by the following normalization equation:
DmodiﬁedN =
Doriginal
If normalization (N) is 1 then two doses were calculated as
the same else doses are different from each other. N graphics
del 6711 up to 1 cm distance.
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r MFig. 7 – Dose normalizations fo
of modiﬁed seeds were plotted individually as cited ID num-
ber of seeds. In the Cartesian analytic system, the calculated
doses were shown on the x-axis that is the transverse axis of
seed. Three kinds of seed are symmetric for all axes so data
were taken on [0 − +Xi]. In N graphics, there are some oscilla-
tions which disturb uniformity of plot curves since they are
plotted in a small scale of the radial axis and data were not
interpolated. Statistical errors of MC  calculations increase as
spatial. Plots of normalized doses are shown in Fig. 6.
Dose normalization of seeds identiﬁed by 2060, 2065, 2074,
2076 and 2077 include considerable deviation of about 10%,
especialy at a small distance (Fig. 6) for [0,1]. Uncertainties are
about 4%–8% while MC dose calculation uncertainties are 0.1%
(histories-initial photon numbers in simulation were selected
as great to acquire maximum 0.1% uncertainties).
Seeds with 2060 and 2065 ID have also remarkable devia-
tions from 1 in N plots of 5 cm length. Deviations are about
Fig. 8 – Dose normalizations for Theragodel 6711 up to 5 cm distance.
3%–7%. Others do not have serious deviations. General char-
acteristic of N plots is deﬁned by decreasing uncertainties
versus increasing distance (Fig. 7). Seed radius has a spatial
line on the x axis where dose was calculated and the radius
is about 0.04 cm N deviations are very big within a compar-
atively short distance in a material space aroun the seed.
Dose has the most effective values to destroy cancerous cell
at a small distance in tissue for LDR (125I and 103Pd) sources.
Uncertainty can exceed 10% in those ragions. At [0,1] dis-
tances, it seems clear that there are great deviations around
the seed. Environs of the seed is an effective area for LDR
therapy.
Looking at Theragenic 200 (Theragenics Corporation) seed
(Fig. 8), normalization values diverge considerably from 1 at
[0,1] distance around the seed capsule. 2281, 2250 and 2274
(Table 3.) seeds show remarkable dose differences from the
original one.
enic 200 Seed up to 1 cm distance.
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In the [0,5] scale distance: 2250, 2257, 2274 and 2281 seeds
Table 3) have clear deviations from 1 cm.  Deviation is around
0%. Statistical uncertainties of dose values increase by dis-
ance. This causes uniformity losses on curves for relative
istant points (Fig. 9).
There are two modiﬁed seeds of ImagySeed (Imagyn
edical Technologies, Inc.) model which have important nor-
alization deviations (Fig. 10). 2311 ID numbered seed has
eviations over 30% and 2329 seed has deviations of about 10%.
2311 and 2329 seeds conserve their deviations on the [0,5]
cale distance. Additionaly, 2328 and 2333 seeds have about
% deviations (Fig. 11).
In the present study, primary dose data were pro-
essed instead of calculating dosimetric functions in Eq. (1).
Fig. 10 – Dose normalizations for Imenic 200 Seed up to 5 cm distance.
Brachytherapy has been used for over 100 years,12,13 and the
brachytherapy dose calculation formalism recommended by
the American Association of Physicists in Medicine AAPM Task
Group No. 43 TG-43 report has been in clinical use for over
15 years.14 Suggestions of the TG-43 formalism have been
challenged by many  studies.15 Dose distributions of modi-
ﬁed seeds were normalized by data belonging to the seeds
assumed as original to make results independent from TG-
43 referenced data. This detailed study that is supported
by literature data proves an optimization for geometrical
properties–dimensions of brachytherapy seeds in MC  calcula-
tions for their size effects on dose. Normalization values show
remarkable deviations which have a serious contribution on
total statistical uncertainties.
agyn Seed up to 1 cm distance.
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4.  Conclusion
Experimental results do not directly require optimized con-
ditions for the seeds since particular and user selective seeds
which have unchanged manufacturing speciﬁcations are used
in the experiment. In MC  studies all effects should be con-
sidered with detail to determine speciﬁc uncertainties. Most
of uncertainties come from geometrical differences, although
ideal conditions were assumed in simulation designs. Conse-
quently, TG-43 data may be revised using optimized MC values
according to geometrical uncertainties. It can be understood
from comparison between seed speciﬁcations (Tables 2–4) and
ratios of normalization deviations that capsule geometry is a
dominant factor for dose amount. In addition, it can be said
that MC  studies on geometrical uncertainties can be useful to
investigate a secondary subject.16 Clinical applications should
be optimized for dimensional deviations of the brachytherapy
seeds since small changes in dimensions cause remarkable
dose deviation as understood from this study. Also dosimet-
ric parameters as suggested in TG-43 report should include
dimension uncertainties.
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